Rallybio to Present at Upcoming Investor Conferences in March
Get Alerts RLYB Hot Sheet
Join SI Premium – FREE
NEW HAVEN, Conn.--(BUSINESS WIRE)-- Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced its participation in the following upcoming investor conferences:
- Cowen 43rd Annual Healthcare Conference in Boston, Massachusetts on Wednesday, March 8, 2023. Martin Mackay, Ph.D., Chief Executive Officer of Rallybio, will participate in a panel discussion, “Neuromuscular & Bone,” at 2:10 p.m. ET.
- Oppenheimer 33rd Annual Healthcare Conference being held virtually on Monday, March 13, 2023. Steve Uden, M.D., President and Chief Operating Officer of Rallybio, will participate in a virtual fireside chat at 4:40 p.m. ET.
A live webcast of both presentations will be accessible through the Events and Presentations section of Rallybio’s website at www.rallybio.com. A replay of the webcasts will be available for 30 days following each presentation.
About Rallybio
Rallybio is a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. Since its launch in January 2018, Rallybio has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of hematology, immuno-inflammation, maternal fetal health, and metabolic disorders. The Company’s mission is being advanced by a team of highly experienced biopharma industry leaders with extensive research, development, and rare disease expertise. Rallybio is headquartered in New Haven, Connecticut, with an additional facility at the University of Connecticut’s Technology Incubation Program in Farmington, Connecticut. For more information, please visit www.rallybio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230224005394/en/
Investor
Ami Bavishi
Head of Investor Relations and Communications
475-47-RALLY (Ext. 282)
[email protected]
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
[email protected]
Media
Tara DiMilia
908-369-7168
[email protected]
Source: Rallybio Corporation
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 3D Files Petition for Provisional Disposition Order Seeking Injunction Against the Invoking of Toho HD’s Poison Pill
- Aberdeen Sets AGM Date
- Veterans Edu Expands U.S. Time-Zone Live Online SAT Classes for Korean Students Abroad
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share